Mirvaso: first treatment for erythema in rosacea

    loading  Checking for direct PDF access through Ovid

Abstract

Mirvaso is the first selective alpha2 agonist to be licensed in the UK for the management of the erythema of rosacea. Here we present the clinical data relating to its efficacy and adverse events and Dr Noreen Cowley comments on its place in therapy.

Related Topics

    loading  Loading Related Articles